Belite Bio, Inc
BLTE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001889109
In the last 90 days, Belite Bio, Inc insiders filed 0 open-market purchases and 4 sales; 80 institutions reported holding it in 13F filings for Q2 2026, worth $1.44B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.
13F holders, Q1 2025
Institutional positions in Belite Bio, Inc as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- −4 vs. Q4 2024
- Shares held
- 149.7K
- −132.8K (−47.0%) vs. Q4 2024
- Total value
- $9.91M
- −$7.91M (−44.4%) vs. Q4 2024
- New holders
- 7
- 5 more added
- Sold out
- 11
- 5 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BLTE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 80 | $1.44B |
| Q1 2026 | 75 | $1.42B |
| Q4 2025 | 69 | $1.15B |
| Q3 2025 | 34 | $169.3M |
| Q2 2025 | 18 | $4.51M |
| Q1 2025 | 18 | $9.91M |
| Q4 2024 | 22 | $17.8M |
| Q3 2024 | 15 | $3.69M |
| Q2 2024 | 11 | $8.52M |
| Q1 2024 | 11 | $2.23M |
| Q4 2023 | 17 | $7.10M |
| Q3 2023 | 7 | $3.17M |
| Q2 2023 | 6 | $14.9M |
| Q1 2023 | 8 | $25.4M |
| Q4 2022 | 7 | $25.9M |
| Q3 2022 | 8 | $3.87M |
| Q2 2022 | 6 | $2.15M |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Belite Bio, Inc; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citigroup Inc | 3 | $199 | 0.00% | +3 | New |
| Advisor Group Holdings, Inc. | 6 | $397 | 0.00% | −1−14.3% | Reduced |
| Tower Research Capital LLC (TRC) | 14 | $927 | 0.00% | +14 | New |
| Caitong International Asset Management Co., Ltd | 49 | $3.25K | 0.00% | +49 | New |
| SBI Securities Co., Ltd. | 104 | $6.89K | 0.00% | +90+642.9% | Added |
| Morgan Stanley | 316 | $20.9K | 0.00% | −10,302−97.0% | Reduced |
| UBS Group AG | 551 | $36.5K | 0.00% | −11,656−95.5% | Reduced |
| Rhumbline Advisers | 1,435 | $95.0K | 0.00% | 00.0% | Unchanged |
| GAMMA Investing LLC | 1,849 | $122.4K | 0.01% | +559+43.3% | Added |
| Virtus Investment Advisers, Inc. | 2,589 | $171.4K | 0.05% | +2,589 | New |
| Ameriprise Financial Inc | 3,075 | $203.6K | 0.00% | +3,075 | New |
| HRT Financial LP | 4,117 | $272.0K | 0.00% | +4,117 | New |
| Bank of America Corp | 5,224 | $345.9K | 0.00% | −13,118−71.5% | Reduced |
| Citadel Advisors LLC | 5,689 | $376.7K | 0.00% | +478+9.2% | Added |
| JPMorgan Chase & Co | 8,162 | $540.5K | 0.00% | −6,474−44.2% | Reduced |
| Geode Capital Management, LLC | 12,753 | $844.5K | 0.00% | +6,053+90.3% | Added |
| State Street Corp | 20,098 | $1.33M | 0.00% | +81+0.4% | Added |
| Alyeska Investment Group, L.P. | 83,623 | $5.54M | 0.02% | +83,623 | New |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −167,930−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −7,062−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −6,326−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −5,865−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −2,450−100.0% | Sold out |
| Virtus ETF Advisers LLC | 0 | $0 | 0.00% | −1,122−100.0% | Sold out |
| Advisors Preferred, LLC | 0 | $0 | 0.00% | −798−100.0% | Sold out |
| Mirae Asset Global Investments Co., Ltd. | 0 | $0 | 0.00% | −357−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −5−100.0% | Sold out |